# A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Source: https://onco.cc/trials/nct06465914/  
OnCo record `nct06465914` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of HPV quadrivalent vaccine in penile cancer, run by Shanghai Bovax Biotechnology Co., Ltd., active and no longer recruiting.

## Summary

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males is a phase 3 interventional study registered as NCT06465914 by Shanghai Bovax Biotechnology Co., Ltd., with 9000 participants enrolled, started 2024-07-11 and due to reach its primary completion in 2027-07-30. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo. Conditions listed: Genital Wart, Penile Cancer, Anal Cancer, PIN-1. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06465914
- Phase: 3
- Setting: A Randomized, Double-blinded, Multicenter and Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Recombinant Vaccine (Hansenula Polymorpha) in Chinese Males Aged 18-45 Years
- Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- Enrolled: 9000

## Sources

- ClinicalTrials.gov NCT06465914: https://clinicaltrials.gov/study/NCT06465914

## Connected records

- cancers: [Penile cancer](https://onco.cc/cancers/penile/)
- drugs: [HPV quadrivalent vaccine (types 6, 11, 16 and 18)](https://onco.cc/drugs/hpv-quadrivalent-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/nct06465914.json